Apexigen announces positive interim results from phase 2 trial evaluating its CD40 antibody, sotigalimab, in combination with doxorubicin in patients with Liposarcoma.

Gary Schwartz, M.D., Chief of Columbia University Medical Center’s Division of Hematology and Oncology and Principal Investigator of the study, as well as members of Apexigen’s senior management team, lead the discussion on the study results.